AbbVie stock jumped Friday after the pharma titan hiked its full-year outlook on the back of strength from its immunology powerhouses Skyrizi and Rinvoq. The duo now completely outearn AbbVie's ...

Johnson & Johnson and AbbVie are two major U.S. pharmaceutical companies with robust pipelines and global operations. Both companies have a strong presence in immunology, oncology and neuroscience ...

An AbbVie research and development lab in San Francisco. (Brian L. Frank for The Wall Street Journal) Drugmaker AbbVie plans to invest more than $10 billion in domestic manufacturing and other ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

AbbVie is poised to grow this year for the first time since Humira's U.S. patent expired. The dividend yields a generous 3.7% and features decades of consistent growth. While tariffs, politics ...

AbbVie Inc. took a little shot at the Trump administration’s trade policy, as the drugmaker said Friday that rather than tariffs, tax reform is the key to boosting U.S. manufacturing. The ...

AbbVie ABBV is gearing up to announce its quarterly earnings on Friday, 2025-04-25. Here's a quick overview of what investors should know before the release. Analysts are estimating that AbbVie ...

Pharmaceutical company AbbVie (NYSE:ABBV) in Q1 CY2025, with sales up 8.4% year on year to $13.34 billion. Its non-GAAP profit of $2.46 per share was 2.6% above analysts’ consensus estimates.